• Urine or s erum pregnancy test (β -HCG) for females of childbearing- potential and women < 12 months since the onset of menopause. • Chemistry: sodium, potassium, chloride, bicarbonate, calcium, glucose, BUN, creatinine, ALT, AST, alkaline phosphatase, total protein, albumin, and total and direct bilirubin. • ACTH, TSH, reflex free T4, lipase, amylase, CRP • Hematology: CBC with differential • Coagulation panel: PT, INR, and PTT 3 STUDY IMPLEMENTATION 3.1 S TUDY DESIGN • This is a phase I/II trial of combination immunotherapy. • The trial will be conducted using a Simon optimal two-stage design . • Participants will receive HPV vaccine + NHS -IL12 + M7824 ( Figure 19). o The first six participants will be evaluable for dose limiting toxicities (DLTs) and accrual will continue to 8 participants if less than 2 out of the first 6 participants experience a DLT . If three or more out of eight patients have objective responses then accrual will be expanded to enroll 20 evaluable participants (Figure 20). Additional patients will be enrolled in the cohort with prior pelvic radiation and boost brachytherapy: up to 12 for safety and dose finding and up to 12 for an exploratory evaluation of efficacy. • There will be a minimum of six days between the first and second participant .